Completed
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Led by Novartis · Updated on 2013-08-15
1461
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.
CONDITIONS
Official Title
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of genital herpes
- Had at least 2 recurrences in past 12 months or 1 recurrence in past 6 months
You will not qualify if you...
- - Currently taking suppressive herpes antiviral therapy
- Females who are pregnant, breast feeding or planning to become pregnant during study
- History of allergy to famciclovir or similar products (e.g. aciclovir, valaciclovir)
Other protocol-defined exclusion criteria may apply.
Trial Site Locations
Total: 1 location
1
Novartis Investigative Site
North Ryde, Australia
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here